News & Events

Press Releases

In the News

Events

SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild to Moderate Alopecia Areata

10 June 2024

READ MORE

SiSaf Announces Completion of Patient Enrolment in Phase II Trial of Bio-Courier Drug Formulation for the Treatment of Mild/Moderate Alopecia Areata

13 December 2023

READ MORE

Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

18 September 2023

READ MORE

FDA Grants SiSaf’s siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation

15 MAY 2023

READ MORE

SiSaf Appoints Dr. Richard Goodfellow to Board of Directors

5 APRIL 2023

READ MORE

SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer

2 MARCH 2023

READ MORE

SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation

12 OCTOBER 2022

READ MORE

SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

12 SEPTEMBER 2022

READ MORE

RNA Therapeutics Company SiSaf to Present at Upcoming Conferences

28 FEBRUARY 2022

READ MORE

SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical Advisor

27 JANUARY 2022

READ MORE

SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease

4 NOVEMBER 2021

READ MORE

SiSaf Ltd utilizes Intoolab’s Tzager AI Platform

29 MARCH 2021

READ MORE

SiSaf Ltd Announces US$13.2 Million Series B Financing

26 NOVEMBER 2020

READ MORE

Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium

2 OCTOBER 2020

READ MORE

SiSaf announces licencing agreement to develop gene therapy for rare bone disease

7 SEPTEMBER 2020

READ MORE

SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research

6 APRIL 2020

READ MORE

SiSaf Establishes Strategic Partnership with Avellino Labs

DEC. 18, 2019

READ MORE

Next

Crossing the Cell Membrane Without Viruses

May 14, 2025

VIEW ARTICLE

Promising Results in Phase 2 Trial of ProSilic

June 10, 2024

VIEW ARTICLE

SiSaf Advances in Alopecia Treatment with Phase II Trial of Bio-Courier^® Technology

December 18, 2023

VIEW ARTICLE

mRNA Revolution: A new generation of medicine.
SiSaf case study

October 4, 2023

VIEW ARTICLE

SiSaf gets green light from FDA for osteopetrosis treatment

May 15, 2023

VIEW ARTICLE

UK osteopetrosis drug granted FDA Orphan Drug status

May 15, 2023

VIEW ARTICLE

Partnership formed to develop miRNA to treat pancreatic cancer

March 2, 2023

VIEW ARTICLE

Delivering RNA Therapeutics through Silicon Stabilized Hybrid Lipid Nanoparticles

November 21, 2022

VIEW ARTICLE

Delivering a New “Post-COVID” Generation of RNA Therapeutics

October 14, 2022

VIEW ARTICLE

SiSaf to seek FDA Orphan Drug Designation for SIS-101-ADO

October 13, 2022

VIEW ARTICLE

SiSaf takes steps with FDA for RNA therapeutic to treat rare genetic skeletal disorders

October 12, 2022

VIEW ARTICLE

SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis

September 12, 2022

VIEW ARTICLE

The challenges and trends of cell & gene therapies

September 6, 2022

VIEW ARTICLE

SiSaf to move siRNA program for bone growth disorder into the clinic

November 11, 2021

VIEW ARTICLE

SiSaf Exercises Option to License Gene Therapy for Rare Bone Disease

November 4, 2021

VIEW ARTICLE

Non-Viral Gene Therapies Get €51M Boost

October 4, 2021

VIEW ARTICLE

Croda International agrees new commercial arrangement with SiSaf

August 2, 2018

VIEW ARTICLE

Next

43rd Annual J.P. Morgan Healthcare Conference

San Francisco
January 13 - 16, 2025

Dr Suzanne Saffie-Siebert, CEO Richard Scarrott, CFO

VIEW EVENT

Jefferies London Healthcare Conference

London
November 19 - 21, 2024

Dr Suzanne Saffie-Siebert, CEO

VIEW EVENT

BioPharma Formulation & Delivery Nexus

London
November 14 - 15, 2024

Dr Michael Welsh, CSO

VIEW EVENT

European Drug Delivery Summit 2024

Frankfurt
June 24 - 25, 2024

Attending:
Dr Suzanne Saffie-Siebert, CEO

VIEW EVENT

mRNA Process Development, Quality & Manufacturing Summit

Vienna
March 26 - 27, 2024

Attending:
Dr Michael Welsh, CSO

VIEW EVENT

42nd Annual J.P. Morgan Healthcare Conference

San Francisco
January 8 - 11, 2024

Attending:
Richard Scarrott, CFO
Dr Michael Welsh, CSO

VIEW EVENT

Bio-Europe 2023

Munich
November 6 - 8, 2023

Attending:
Dr Michael Welsh, CSO

VIEW EVENT

3rd International Conference on Carbon Chemistry and Materials

Paris
October 23 - 27, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO

VIEW EVENT

23rd Annual Biotech in Europe Forum

Basel
September 20 - 21, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO
Richard Scarrott, CFO

VIEW EVENT

Bio€quity Europe 2023

Dublin
May 14 – 16, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO Richard Scarrott, CFO

VIEW EVENT

Advances in Achondroplasia Conference 2023

Frankfurt/Main

April 21 – 22, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO

VIEW EVENT

2nd Annual mRNA-Based Therapeutics Summit

Europe Berlin

January 24 – 26, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO

VIEW EVENT

JPM 2023 41st Annual Healthcare Meeting

San Francisco

January 9 – 12, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO Richard Scarrott, CFO

VIEW EVENT

BIO-Europe

Berlin

October 24 – 26, 2022

Attending:
Dr Michael Welsh, CSO Dr Spiros Servos, BD

VIEW EVENT

RNA Leaders USA Congress

Boston

October 18 – 19, 2022

Attending:
Dr Suzanne Saffie-Siebert, CEO Richard Scarrott, CFO

VIEW EVENT

ARM Cell & Gene Meeting on the Mesa

October 11 – 13, 2022

Attending:
Dr Spiros Servos, BD

VIEW EVENT

Next